Livivos inks arrangement with Pfizer.
SAN DIEGO, October 6, 2022— Livivos, Inc., a San Diego-based biomedical device technology startup, signed a usage agreement with Pfizer, Inc., the world’s number one pharmaceutical company in 2021 revenue rankings. Pfizer will conduct an investigation of Livivos’s LiverScope®, an innovative, Point-of-Care liver disease diagnostic device.
Livivos’s LiverScope® is a device that conducts assessments of fatty liver disease, a condition with steadily increasing global prevalence that has been linked to cardiovascular disease and diabetes and can progress to more serious liver disorders. Currently, fatty liver disease can be diagnosed with MRI scanners, but these are expensive, bulky, require dedicated shielded rooms and trained technicians, and can induce claustrophobia in patients. Like MRI, the LiverScope® is based on magnetic resonance, but it is much simpler to operate, and achieves results in a small, quiet, open, table-based form factor that can be operated in a clinic or even a van, allowing a mobile scanning service. The LiverScope® is not yet FDA cleared.
Pfizer will assess the LiverScope’s® measurement of Proton Density Fat Fraction (PDFF), a quantitative biomarker of fatty liver disease, over a six month period.
Currently, fatty liver disease can be diagnosed with MRI scanners, but these are expensive, bulky, require dedicated shielded rooms and trained technicians, and can induce claustrophobia in patients. Like MRI, the LiverScope® is based on magnetic resonance, but it is much simpler to operate, and achieves results in a small, quiet, open, table-based form factor that can be operated in a clinic or even a van, allowing a mobile scanning service.
Livivos’s mission is to make liver disease diagnosis broadly available by providing accurate, rapid, and accessible Point-of-Care assessment and this grant is a big step down our device performance evaluation path.